AstraZeneca at #ASCO23 (Photo: Senior editor Max Gelman for Endpoints News)

As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

CHICA­GO — As­traZeneca and Dai­ichi Sankyo’s En­her­tu showed promis­ing ef­fi­ca­cy in a range of can­cers — par­tic­u­lar­ly gy­ne­co­log­ic can­cers — that ex­press the bio­mark­er HER2, ac­cord­ing to a study re­leased at AS­CO’s an­nu­al meet­ing on Mon­day.

The Phase II, open-la­bel tri­al could pave the way for En­her­tu for a num­ber of new in­di­ca­tions down the line, such as en­dome­tri­al and cer­vi­cal can­cers, and in can­cers where HER2 test­ing is not the norm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.